Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

8.450 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Monkeypox Vaccine Maker Bavarian Nordic Bets $380M On Emergent Bio's Travel Vaccines ↗
 
Via Benzinga
News headline image
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions (EBS) Q3 2022 Earnings Call Transcript ↗
EBS earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
News headline image
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot ↗
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. 
Via Benzinga
News headline image
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 64 companies achieved new lows for the year. 
Via Benzinga
News headline image
EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023 ↗
SAB Biotherapeutics' (NASDAQ: SABS) Q3 net loss reached $(7.1) million, equivalent to an EPS loss of $(0.16), as compared to a net loss of $(4.1) million a year ago. Cash and cash equivalents were $8.3... 
Via Benzinga
News headline image
Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
News headline image
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target ↗
 
Via Benzinga
News headline image
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing ↗
Biotech stocks were hammered Wednesday, including several that had good news. 
Via Investor's Business Daily
News headline image
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday ↗
 
Via Benzinga
News headline image
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
From Emergent BioSolutions
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst ↗
Although blue chips provide greater predictability, these top small-cap stocks to buy may drive intense growth for speculators. 
Via InvestorPlace
News headline image
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study ↗
Emergent BioSolutions (NYSE: EBS) has dosed first patient in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV in healthy subjects. EBS-LASV is a recombinant VSV-vectored Lassa... 
Via Benzinga
News headline image
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox ↗
 
Via Benzinga
News headline image
3 Top Monkeypox Stocks to Buy Right Now ↗
With cases of a frightening disease spreading to all 50 states, it’s now time to consider the top monkeypox stocks to buy right now. 
Via InvestorPlace
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.